PMID: 11921114Mar 29, 2002Paper

Clinical-pathological study of levodopa complications

Movement Disorders : Official Journal of the Movement Disorder Society
Azi H RajputOleh Hornykiewicz

Abstract

We sought to determine the continued benefit and the pattern of motor complications of long-term levodopa treatment in Parkinson's disease. Patients were evaluated between 1968 and 1996. Only those who had an adequate levodopa trial and in whom autopsy revealed Lewy body Parkinson's disease were included. Total levodopa and mean daily dose were calculated in each case. Dyskinesia, wearing-off and on-off were collectively classified as motor adverse effects and reported as cumulative incidence. Forty-two patients (male, 30; female, 12) with mean 15.9 years of illness and 9.1 years follow-up received on average 500-mg levodopa daily over 9.8 years. Seventeen of 21 patients assessed during the last 18 months of life reported some motor benefit. Adverse effects were seen in 71.4% of patients. The most common was dyskinesia, in 61.9%; wearing-off in 35.7%; and on-off in 16.7% of patients. The earliest adverse effect was dyskinesia and the last to emerge was on-off. Isolated dyskinesia was seen in 35.7% and wearing-off in 7.1% of patients; 15.5% of patients developed dyskinesia after 2.6 years and 31% after 6.4 years on levodopa. We concluded that levodopa benefit declined and adverse effects increased with time. Dyskinesia was the e...Continue Reading

References

Nov 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·A J HughesA J Lees
Mar 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·A J HughesA J Lees
Aug 1, 1991·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·A H RajputA Rajput
Oct 1, 1991·Brain : a Journal of Neurology·J M Fearnley, A J Lees
Dec 1, 1990·Clinical Neuropharmacology·A H RajputL Ang
Sep 1, 1990·Neurology·R A RoosE A van der Velde
Jun 1, 1989·Annals of Neurology·A H RajputB Rozdilsky
May 1, 1989·Neurology·R C Duvoisin, L I Golbe
Oct 1, 1986·Annals of Neurology·L S FornoG A Ricaurte
Jul 1, 1987·Annals of Neurology·G J de JongP I Schmitz
Feb 16, 1967·The New England Journal of Medicine·G C CotziasL M Schiffer
May 1, 1967·Neurology·M M Hoehn, M D Yahr
Oct 1, 1982·Archives of Neurology·A H RajputP Seeman
Feb 1, 1981·Neurology·C H Markham, S G Diamond
Apr 1, 1994·Annals of Neurology·A H RajputO Hornykiewicz
Apr 1, 1994·Journal of Neurology, Neurosurgery, and Psychiatry·A J HughesA J Lees
Jul 1, 1993·Journal of Geriatric Psychiatry and Neurology·A H RajputA Rajput
Aug 1, 1996·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·P J BlanchetP J Bédard
Feb 1, 1997·Neurology·D E MoulinA Hahn
May 1, 1997·Neurology·M C de RijkD M Maraganore
May 1, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·J G NuttW R Woodward
Sep 26, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·P R SchuurmanD A Bosch
Oct 2, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·P J BlanchetT N Chase
Oct 2, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·A H RajputN Galvez-Jimenez
Oct 2, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·D G Le Couteur, S J McCann

❮ Previous
Next ❯

Citations

Sep 1, 2006·Experimental Brain Research·Sarah LemieuxChristian Duval
Oct 14, 2005·Journal of Neurology·Fabrizio Stocchi
May 4, 2004·Parkinsonism & Related Disorders·Ali H RajputOleh Hornykiewicz
Jul 2, 2005·Nature Genetics·Anna C NeedDavid B Goldstein
Sep 11, 2012·Brain : a Journal of Neurology·YaJun ZhangCristina M Bäckman
May 4, 2012·Cold Spring Harbor Perspectives in Medicine·Martin NiethammerDavid Eidelberg
Nov 29, 2007·Neuroepidemiology·Dirk WoitallaDoris-Anita Haeger
Nov 26, 2013·International Journal of Pharmaceutics·Xiang LiYouxin Li
Sep 10, 2002·Parkinsonism & Related Disorders·Ali H Rajput
Feb 10, 2006·Expert Review of Neurotherapeutics·Alex Rajput, Ali H Rajput
Mar 6, 2007·Expert Opinion on Drug Delivery·Y Naidu, K Ray Chaudhuri
Jun 30, 2006·Expert Opinion on Pharmacotherapy·Fabrizio Stocchi
Sep 24, 2015·Current Medical Research and Opinion·Zhi-Jun LiChen-Ju Yi
Jul 21, 2015·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Leslie Wayne FergusonAlexander Rajput
Dec 5, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Mikko KuoppamäkiPeter Jenner
Mar 7, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Frédéric CalonThérèse Di Paolo
Aug 10, 2015·Neuropharmacology·Nicolas MorinThérèse Di Paolo
Mar 17, 2009·Journal of Neuropathology and Experimental Neurology·Pershia SamadiThèrèse Di Paolo
Sep 8, 2010·Parkinsonism & Related Disorders·A H RajputA Rajput
Feb 7, 2009·Parkinsonism & Related Disorders·Laurent GrégoireThérèse Di Paolo
Jun 20, 2008·Experimental Neurology·Torun MalmlöfBjörn Schilström
Sep 11, 2007·Progress in Neurobiology·Micaela MorelliMichael A Schwarzschild
Apr 3, 2007·Trends in Neurosciences·M Angela Cenci
Sep 17, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·C Warren OlanowFabrizio Stocchi
Sep 11, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Peter Jenner
Sep 1, 2006·Journal of Neurochemistry·M Angela Cenci, Martin Lundblad
Mar 14, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Yoshikuni MizunoUNKNOWN Japanese Istradefylline Study Group
Apr 4, 2016·Biochemical Pharmacology·Marc MorissetteThérèse Di Paolo
Sep 13, 2005·Parkinsonism & Related Disorders·Francisco Pereira da Silva-JúniorVeralice Meireles Sales de Bruin
Dec 29, 2009·Neurobiology of Aging·Bazoumana OuattaraThérèse Di Paolo
Jun 23, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Miho MurataUNKNOWN Japan Zonisamide on PD Study Group
Oct 3, 2003·Expert Opinion on Pharmacotherapy·Janet RomrellMichael S Okun
Jun 18, 2015·Frontiers in Aging Neuroscience·Jacob J Crouse, Ahmed A Moustafa
Mar 26, 2015·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Ali H Rajput, Alex Rajput

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Movement Disorders : Official Journal of the Movement Disorder Society
J E Ahlskog, M D Muenter
Movement Disorders : Official Journal of the Movement Disorder Society
Leo Verhagen MetmanT N Chase
Movement Disorders : Official Journal of the Movement Disorder Society
J E RicePhilip D Thompson
© 2022 Meta ULC. All rights reserved